NEULANDLAB vs SENORES: Stock Comparison
NEULAND LAB is the larger company by market capitalisation. NEULAND LAB shows a higher ROE, a higher dividend yield and faster revenue growth, while SENORES PHARMACEUTICALS L shows a lower P/E and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
NEULANDLAB leads 7; SENORES leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | NEULANDLAB | SENORES |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | NEULANDLAB | SENORES |
|---|---|---|
| Live Price | ₹22,660 | ₹1,428.4 |
| Day Change | -1% | -0.14% |
| Volume | 21,110 | 1.24 L |
| 52-Week High | ₹23,881 | ₹1,599 |
| 52-Week Low | ₹11,500 | ₹662.45 |
| Distance from 52W High | -5.11% | -10.67% |
Valuation
| Metric | NEULANDLAB | SENORES |
|---|---|---|
| Market Cap | ₹29,101 Cr | ₹6,582 Cr |
| P/E Ratio | 59.08x | 50.84x |
| P/B Ratio | 15.69x | 7.16x |
| EPS | ₹115.1 | ₹6.67 |
| Book Value | ₹1,461.02 | ₹209.44 |
| Dividend Yield | 0.15% | 0% |
Growth
| Metric | NEULANDLAB | SENORES |
|---|---|---|
| Revenue Growth (TTM YoY) | 136.4% | 53.4% |
| EPS Growth (TTM YoY) | 664.4% | 108.9% |
| Qtr Sales Growth | 0% | 567.69% |
| Qtr Profit Growth | 0.21% | 2,856.31% |
Profitability & Leverage
| Metric | NEULANDLAB | SENORES |
|---|---|---|
| ROE | 19.46% | 12.6% |
| ROCE | 19.06% | 11.43% |
| Net Margin | 17.99% | 18.5% |
| Operating Margin | 25.29% | 28.35% |
| Debt to Equity | 0.11x | 0.34x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | NEULANDLAB | SENORES |
|---|---|---|
| Promoter Holding | 32.62%▼ 0.01 pp | 39.54% |
| FII Holding | 21.08%▲ 0.62 pp | 6.62%▲ 2.98 pp |
| DII Holding | 16.51%▲ 0.67 pp | 9.77%▲ 0.16 pp |
| Public Holding | 29.79%▼ 1.28 pp | 37.79%▼ 3.14 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NEULAND LAB and SENORES PHARMACEUTICALS L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.